Skip to main content

Advertisement

Table 2 Counts of potentially novel drug-drug interaction claims

From: Dynamic enhancement of drug product labels to support drug safety, efficacy, and effectiveness

Drug Number of VA-NDFRT DDIs Number of VA-NDFRT DDIs that were potentially novel
  found for the drug to at least one product label. N (%)
  Significant Critical Significant Critical
Amitriptyline 16 8 8(50) 3 (38)
Amoxapine 15 8 11 (73) 4 (50)
Bupropion 7 4 5 (71) 3 (75)
Citalopram 25 9 5 (20) 4 (44)
Desipramine 16 10 16 (100) 6 (60)
Doxepin 15 9 15 (100) 9 (100)
Duloxetine 26 8 12 (46) 3 (38)
Escitalopram 13 3 3 (23) 1 (33)
Fluoxetine 51 14 28 (55) 8 (57)
Imipramine 18 10 18 (100) 6 (60)
Mirtazapine 2 5 1 (50) 1 (20)
Nefazodone 39 20 31 (80) 11 (55)
Nortriptyline 16 11 16 (100) 11 (100)
Paroxetine 33 11 15 (46) 5 (45
Selegiline 2 47 1 (50) 23 (49)
Sertraline 28 8 7 (25) 3 (38)
Tranylcypromine 3 61 1 (33) 33 (54)
Trazodone 8 10 8 (100) 10 (100)
Trimipramine 17 10 17 (100) 10 (100)
Venlafaxine 21 6 21 (100) 6 (100)
  1. The number and proportion of VA NDF-RT drug-drug interactions that were noted as potentially novel to the Drug Interaction section of at least one antidepressant product label. For these drugs, a potentially novel interaction was an NDF-RT interaction that was 1) not mentioned in the Drug Interaction section of a drug’s product label based on a case-insensitive string match, and 2) not listed as an interacting drug based on our review (prior to the study) of a single manually-reviewed product label the listed drug.